In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy

Abstract

Background To study in vitro the effects of anlotinib combined with radiotherapy on the lung cancer H520 cell cycle and apoptosis. Methods The log growth period H520 cells were divided into the control group, anlotinib group (A group), radiotherapy group (RT group) and combined group (A + RT group). Cell cycle and apoptosis were detected by flow cytometry and changes in H520 cell cycle and apoptosis were analyzed in each group. Results Anlotinib was determined to significantly inhibit cell growth in all groups, both alone, or in combination with radiotherapy. After receiving corresponding treatments, the proportions of G2/M‐phase cells in the control group, A group, RT group and A + RT group were different, and statistically significant (F = 32.086, P < 0.001). The apoptotic cell statistics of H520 cells in the control group, A group, RT group and A + RT group were significantly different (F = 44.537, P < 0.01). The relative expression of CDK1 in each group of cells was 0.04 ± 0.02, 0.07 ± 0.12, 0.81 ± 0.11, and 0.56 ± 0.16, respectively. There were differences between the groups by analysis of variance which were statistically significant (F = 58.36, P < 0.0001). The relative expression of cycle B in each group of cells was 0.27 ± 0.05, 0.40 ± 0.16, 0.65 ± 0.14, and 0.57 ± 0.13, respectively. There were differences between the groups by analysis of variance which were statistically significant (F = 10.77, P = 0.0002). Conclusions Anlotinib had an inhibitory effect on lung cancer H520 cell proliferation. A higher rate of apoptosis and G2/M phase block was observed in the anlotinib‐radiotherapy combined group. Anlotinib combined with radiotherapy was able to synergistically inhibit tumor cell growth. Key points Anrotinib combined with radiotherapy can synergistically inhibit tumor cell growth.

Anlotinib induces tumor blood vessel normalization to strengthen the anticancer effect of radiotherapy on esophageal cancer by inhibiting EphA2

“…Our study also mentioned that Anlotinib also exhibited great effects on promoting the e cacy of radiotherapy in EC. Consistently, it is noted that in the setting of lung cancer, the synergism of radiotherapy and Anlotinib is more effective to suppress cell proliferation and tumor cell growth than administration of Anlotinib alone [23]. Overall, Anlotinib is a promising drug for managing the process of cancer and improving the survival of cancer patients; moreover, Anlotinib and radiotherapy synergistically function to control tumorigenic activities of malignant cells.…”

Anlotinib Inhibits Tumor Angiogenesis and Promotes the Anticancer Effect of Radiotherapy on Esophageal Cancer through Inhibiting EphA2

“…Our study also mentioned that anlotinib also exhibited great effects on promoting the efficacy of radiotherapy in EC. Consistently, it is noted that in the setting of lung cancer, the synergism of radiotherapy and anlotinib is more effective to suppress cell proliferation and tumor cell growth than the administration of anlotinib alone [ 25 ]. Overall, anlotinib is a promising drug for managing the process of cancer and improving the survival of cancer patients; moreover, anlotinib and radiotherapy synergistically function to control the tumorigenic activities of malignant cells.…”

Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study

“…Anlotinib combined with radiotherapy synergistically inhibits the growth of tumour cells. 24 Cranial radiotherapy can increase the permeability of the BBB, which may increase anlotinib content in brain tissue; thus, the curative effect of cranial radiotherapy combined with anlotinib may be superior to that of cranial radiotherapy alone for NSCLC patients with no specific gene mutation. 25 A previous retrospective study 26 and 2 prospective studies 27 , 28 suggested that anlotinib combined with radiotherapy for BM has satisfactory efficacy with tolerable toxicity.…”